Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Active, not recruiting · Phase 1 · NCT03821935
Conditions: Advanced Solid Tumors Cancer
At a glance
- Research payments reported, 2025
- $1.2M
- U.S. investigators named
- 21
- Sites paid
- 23
- Planned or actual enrollment
- 364
About the trial
- Sponsor
- AbbVie
- Tested
- Livmoniplimab (drug), Budigalimab (drug)
- Dates
- Started 2019-02-21; completion 2027-06
- Results posted
- Not yet
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.
From ClinicalTrials.gov, last updated 2025-05-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $1.2M in research payments for this study in 2025 (101 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- J T. Beck, M.D., F.A.C.P. Hematology & Oncology · Springdale, AR
- Joshua G. Cohen, M.D. Gynecologic Oncology · Irvine, CA
- Michael Cecchini, MD Hematology & Oncology · New Haven, CT
- Guru P. Sonpavde, MD Medical Oncology · Orlando, FL
- John Moroney Gynecologic Oncology · Chicago, IL
- Gregory A. Durm, MD Hematology & Oncology · Indianapolis, IN
- Kathy D. Miller, MD Hematology & Oncology · Indianapolis, IN
- Bert H. O'neil, MD Medical Oncology · Indianapolis, IN
- Kian Lim, MD Medical Oncology · Saint Louis, MO
- Rodney P. Rocconi, MD Gynecologic Oncology · Jackson, MS
- Elizabeth V. Connor, MD Gynecologic Oncology · Billings, MT
- Matthew D. Galsky, MD Medical Oncology · New York, NY
- Naoko Takebe, M.D. PHD. Hematology & Oncology · Rochester, NY
- David R. Wise, M.D., PH.D. Medical Oncology · New York, NY
- Marcia R. Cruz-correa, MD Gastroenterology · Rio Piedras, PR
- Benjamin Garmezy, MD Hematology & Oncology · Nashville, TN
- Kai He, MD, PHD Medical Oncology · San Antonio, TX
- Jonathan Lu Hematology & Oncology · Tomball, TX
- Haroutioun S. Shahinian, M.D. Hematology & Oncology · El Paso, TX
- Anthony W. Tolcher Medical Oncology · San Antonio, TX
- Elizabeth M. Swisher Gynecologic Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Washington Medical Ctr, WA $329,733
- Sarah Cannon Research Institute LLC $327,724
- Washington University $98,042
- The Ohio State University $76,812
- Board of Regents of the University of Oklahoma $69,011
- Yale University $56,052
- City of Hope National Medical Ctr $49,600
- Intermountain Health St Vincent Regional Hospital, MT $41,261
- Renovatio Clinical $24,550
- The University of Chicago $21,905
- Pan American Center for Oncology $20,350
- University of Mississippi Med Center, MS $20,000
- Icahn School of Med at Mt Sinai $19,678
- Community Hospital East, IN $11,908
- Sarah Cannon Research Institute $11,850
- New York University $9,287
- Highlands Oncology Group PA $6,824
- Mount Sinai School of Medicine $3,850
- Indiana University $3,650
- New Experimental Therapeutics $3,525
- Adventhealth Orlando, FL $3,183
- Highlands Oncology Group $2,500
- Indiana University Health Center $1,750
- $675
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.